الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 255 |  |  |
| | | from | 255 | | |
Abstract
Background: Hepatitis C virus (HCV) is a major health problem worldwide. Its long-term impact ranges from minimal damage to extensive fibrosis and cirrhosis, which is sometimes, accompanied by hepatocellular carcinoma (HCC).
Aim of the Work: To evaluate early changes of hepatic fibrosis-related parameters in patients with chronic HCV patients using liver stiffness measurement using Shear wave elastography (Siemens-Acuson S2000) and serum parameters as APRI, FIB4 before and after sofosbuvir-based antiviral therapy.
Patients and Methods: This study were conducted on 109 Egyptian patients with chronic hepatitis C who were collected from viral hepatitis treatment unit in Sohag Cardiology and Hepato-Gastroentrology Center and followed up in the period between July 2017 and September 2018.
Results: The mean age of the studied patients was 45.76 ±13.91 years, 67 (61.50%) of them were males while 42 (38.50%) were females. A history of diabetes was reported in 8 (7.30%) patients, 11 (10.10%) of our patients were hypertensive while 3 (2.80%) patients were ischemic heart disease. A total of 109 HCV-infected patients treated with sofosbuvir based therapy for 12 weeks were identified, 84 (77.10%) were treated with sofosbuvir 400 mg/day and daclatasvir 60 mg/day and 25 (22.90%) were treated with sofosbuvir 400 mg/day and daclatasvir 60 mg/day with weight-based ribavirin (1000 mg { below 75 kg} to 1200 mg {above 75mg}).
Conclusion: Sofosbuvir-based treatment regimens for CHC result in significant reduction in Liver stiffness measurements (LSM) by pSWE with significant changes in the distribution of patients among the fibrosis stages except liver fibrosis stage 4 (F4) and significant improvement in fibrosis scores (FIB4 and APRI) 24 weeks post treatment.